Derek Erion, Ph.D.
Chief Scientific Officer
Dr. Erion has more than 15 years of experience in the pharmaceutical industry, focused on discovering novel therapeutics for diseases with high unmet medical need across diverse modalities.
Most recently, he served as Vice President, Head of Disease Area Biology at Korro Bio, where he led efforts in RNA editing for targets in the liver and central nervous system. Prior to Korro Bio, he was Director in the GI Drug Discovery Unit at Takeda Pharmaceuticals, driving programs aimed at treating liver diseases. Earlier in his career, he was a lab head in Pfizer’s Cardiovascular Metabolic Disease Research Unit, leading a team of in vitro and in vivo scientists.
Dr. Erion earned dual bachelor’s degrees in Chemistry and Biology from the University of California, Irvine, and a Ph.D. in Physiology from Yale University. He has authored more than 45 publications covering a wide range of biological mechanisms and therapeutic modalities.